ArticleBMC infectious diseases2026
Endocan as a marker of plasma leakage in dengue patients: a diagnostic study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasma leakage is a key manifestation of severe dengue, but current recommended diagnostic methods by the World Health Organization (WHO) have several limitations. Endothelial cells (ECs) activation and dysfunction are known to play a central role in plasma leakage. Endocan, a proteoglycan produced by activated ECs, has been shown to correlate with disease severity in dengue infection. This study aimed to evaluate endocan as a potential marker of plasma leakage in dengue infection.
methodsThis retrospective cohort study utilized data from the International Study on Biomarkers and Gene Expression Patterns in Patients with Dengue Virus Infection (INVEST), collected from 2010 to 2011 at Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Endocan levels were measured by ELISA and plasma leakage was diagnosed with ultrasonography (USG). Receiver Operating Characteristic (ROC) curve analysis was performed to determine the endocan cut-off level for detecting plasma leakage. Correlation tests were conducted to examine the relationships between endocan, hematocrit, delta hematocrit, and albumin levels. Data were analyzed using GraphPad Prism versi 5.0 for Windows and SPSS version 28.
resultsAmong 64 patients ((31 dengue fever (DF) and 33 dengue hemorrhagic fever (DHF)), significant differences in endocan levels, thrombocyte count, delta hematocrit, and albumin were found between DF and DHF patients. The area under the curve (AUC) for endocan was 0.83 (95% (CI): 0.73–0.93). A cut-off value of 1.63 ng/mL for endocan demonstrated a sensitivity of 66.7%, specificity of 90.3%, positive predictive value of 88%, and negative predictive value of 71.8%. Furthermore, a negative correlation was found between endocan and albumin levels during the critical phase of dengue (r: -0,4; p: 0,001).
conclusionWe observed a significant increase in endocan levels, mainly during the critical phase of dengue patients with plasma leakage. Our findings indicate that endocan could serve as a novel marker for detecting plasma leakage in dengue patients, demonstrating high specificity. Nevertheless, further validation studies in other populations are necessary to confirm the role of endocan as a marker for plasma leakage in dengue infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.